Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Feb 20;318(7182):502-7.
doi: 10.1136/bmj.318.7182.502.

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group

K D Bardhan  1 , S Müller-Lissner, M A Bigard, G Bianchi Porro, J Ponce, J Hosie, M Scott, D G Weir, K R Gillon, R A Peacock, C Fulton
Affiliations
Clinical Trial

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group

K D Bardhan et al. BMJ. .

Abstract

Objective: To assess intermittent treatment over 12 months in patients with symptomatic gastro-oesophageal reflux disease.

Design: Randomised, multicentre, double blind, controlled study. Patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. Patients remaining symptomatic had omeprazole 10 mg or ranitidine dose doubled for another 2 weeks while omeprazole 20 mg was continued for 2 weeks. Patients who were symptomatic or mildly symptomatic were followed up for 12 months. Recurrences of moderate or severe heartburn during follow up were treated with the dose which was successful for initial symptom control.

Setting: Hospitals and primary care practices between 1994 and 1996.

Subjects: 677 patients with gastro-oesophageal reflux disease.

Main outcome measures: Total time off active treatment, time to failure of intermittent treatment, and outcomes ranked from best to worst.

Results: 704 patients were randomised, 677 were eligible for analyses; 318 reached the end of the study with intermittent treatment without recourse to maintenance antisecretory drugs. The median number of days off active treatment during follow up was 142 for the entire study (281 for the 526 patients who reached a treatment related end point). Thus, about half the patients did not require treatment for at least 6 months, and this was similar in all three treatment groups. According to outcome, 378 (72%) patients were in the best outcome ranks (no relapse or one (or more) relapse but in remission until 12 months); 630 (93%) had three or fewer relapses in the intermittent treatment phase. Omeprazole 20 mg provided faster relief of heartburn. The results were similar in patients with erosive and non-erosive disease.

Conclusions: Intermittent treatment is effective in managing symptoms of heartburn in half of patients with uncomplicated gastro-oesophageal reflux disease. It is simple and applicable in general practice, where most patients are seen.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Calculation of total time off treatment
Figure 2
Figure 2
Distribution of total number of days off treatment for 677 patients (all patients treated analysis)
Figure 3
Figure 3
Time to failure of intermittent treatment in 677 patients (all patients treated analysis)
See this image and copyright information in PMC

References

    1. Hungin APS, Rubin GP, O’Flanagan H. How regularly do patients on long term PPIs take their therapy? Gastroenterology. 1997;112:A19.
    1. Staerk Laursen L, Havelund T, Bondesen S, Hansen J, Sanchez G, Sebelin E, et al. Omeprazole in the long term treatment of gastro-oesophageal reflux disease. A double-blind randomised dose finding study. Scand J Gastroenterol. 1995;30:839–846. - PubMed
    1. Zeitoun P, Isal JP, Barbier P. Comparison of two dosage regimens of omeprazole—10mg once daily and 20mg weekends—as prophylaxis against recurrence of reflux oesophagitis. Hepatogastroenterol. 1989;36:279–280.
    1. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double-blind trial of their efficacy and safety. Gut. 1995;35:590–598. - PMC - PubMed
    1. Vigneri S, Termini R, Leandro G, Badalamenti S, Panatalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux oesophagitis. N Engl J Med. 1995;333:1106–1110. - PubMed